MedTrace Logo

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

NCT06014528 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-04-30

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).

Conditions

  • Ovarian Cancer Recurrent

Interventions

DRUG

IN10018

100mg QD orally (PO)

DRUG

Placebo of IN10018

100mg QD orally (PO)

DRUG

Pegylated Liposomal Doxorubicin

40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)

Sponsors & Collaborators

  • InxMed (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lingying WU · Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-06
Primary Completion
2026-12-24
Completion
2026-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014528 on ClinicalTrials.gov